Compare Infosys Limited (INFY) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Infosys Limited vs Sanofi SA — how do they compare? Infosys Limited trades at $10.74 (market cap $41.74B), while Sanofi SA trades at $40.04 (market cap $95.18B). The key difference: Sanofi SA is far larger — about 2.3× Infosys Limited's market cap, and Sanofi SA pays the higher dividend (6.01%). Which is the better fit depends on your goals — on Pluang, investors hold Infosys Limited for 27 Days and Sanofi SA for 94 Days on average.
| INFY | SNY | |
|---|---|---|
Market Cap | $41.74B | $95.18B |
Volume | 31,354,285 | 2,995,646 |
Sector | Technology | Health |
52-Week High | $20.22 | $52.34 |
52-Week Low | $10.49 | $39.51 |
Typical Hold Time | 27 Days | 94 Days |
Enterprise Value | $39.48B | $114.48B |
Dividend Yield | 4.89% | 6.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INFY trades at $10.75, up 1.9% in the last 24 hours, with a bearish technical signal from moving averages. The company reported a net income of $3.16B on $19.28B revenue for 2025, with profitability metrics like a 16.37% net margin and 32.12% ROE. Recent news highlights strategic AI collaborations, such as with Columbia University and ABN Amro, to drive innovation. Earnings have been mixed, with beats in Q4 2025 and Q1 2026 but a miss in Q2 2026.
The outlook is cautious; while valuation ratios like a P/E of 13.21 appear reasonable and analyst consensus targets $11.48, weak IT spending and AI pricing pressure pose risks. Institutional sentiment is mixed with 35% buy ratings, but negative cash flow trends in 2026 forecast demand careful monitoring of execution against guidance.
SNY trades at $40.17, down slightly by 0.07%. The technical outlook is bearish, with price near key support at $40. Fundamentally, the company reported strong Q2 2026 earnings, beating estimates with EPS of $1.21, and revenue for 2025 reached $46.72B. Recent news highlights a significant $8B immunology alliance expansion with Regeneron, signaling growth potential beyond its blockbuster drug Dupixent.
The stock presents a mixed outlook. Positive factors include consistent earnings beats, a high gross margin of 72.77%, and strategic partnerships. However, a bearish technical signal, a projected net income decline to $4.0B in 2026, and a high proportion of analyst hold ratings (51.86%) suggest caution. Key risks involve execution of new drug pipelines and future patent expirations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Infosys Limited
Infosys is a global leader in next-generation digital services and consulting. It enables clients in more than 50 countries to navigate their digital transformation through AI-powered cloud and data solutions.
Read more on INFY →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
